Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [LNCaP/AR/shTP53/shRB1]

ABSTRACT: ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [LNCaP/AR/shTP53/shRB1]

PROVIDER: PRJNA934548 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23379860_1.fastq.gz	Fastqsanger.gz
	SRR23379860_2.fastq.gz	Fastqsanger.gz
	SRR23379861_1.fastq.gz	Fastqsanger.gz
	SRR23379861_2.fastq.gz	Fastqsanger.gz
	SRR23379862_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [LNCaP/AR/shTP53/shRB1]

Project description:Here we demonstrated that the RNA-binding protein ELAVL3 is specifically upregulated in NEPC, and that overexpression of ELAVL3 alone sufficiently induce neuroendocrine phenotype in prostate adenocarcinoma. Pharmacological inhibition of ELAVL3 with pyrvinium pamoate, an FDA-approved drug, effectively suppressed tumor growth, reduced the risk of metastases, and improved the survival of NEPC mice models.

2023-10-23 | GSE224909 | GEO